Bicalutamide
- Generic Name
- Bicalutamide
- Brand Names
- Casodex
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14F4N2O4S
- CAS Number
- 90357-06-5
- Unique Ingredient Identifier
- A0Z3NAU9DP
- Background
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
- Indication
Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.
- Associated Conditions
- Metastatic stage D2 Prostatic carcinoma
- Associated Therapies
- -
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 48
- Registration Number
- NCT00651326
- Locations
- 🇨🇦
McGill University - Dept. Oncology, Montreal, Canada
🇨🇦Tom Baker Cancer Centre, Calgary, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Canada
Casodex - Nolvadex Combination
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00637871
Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2015-01-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT00631527
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 36
- Registration Number
- NCT00630344
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-01-09
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT00589472
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCSF Medical Center-Parnassus, San Francisco, California, United States
Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
- Conditions
- Interventions
- First Posted Date
- 2008-01-07
- Last Posted Date
- 2016-03-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT00586898
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2007-10-30
- Lead Sponsor
- Wirral University Teaching Hospital NHS Trust
- Target Recruit Count
- 42
- Registration Number
- NCT00551044
- Locations
- 🇬🇧
Wirral University Teaching Hospitals NHS Trust, Upton, Wirral, Merseyside, United Kingdom
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 29
- Registration Number
- NCT00544830
- Locations
- 🇺🇸
City of Hope South Pasadena, South Pasadena, California, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- University College, London
- Target Recruit Count
- 4236
- Registration Number
- NCT00541047
- Locations
- 🇨🇦
London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
🇨🇦Ottawa Health Research Institute, Ottawa, Ontario, Canada
🇬🇧Lincoln County Hospital, Lincoln, England, United Kingdom
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 80
- Registration Number
- NCT00528866
- Locations
- 🇺🇸
Mary Bird Perkins Cancer Center - Baton Rouge, Baton Rouge, Louisiana, United States
🇺🇸Mercy Cancer Center at Mercy San Juan Medical Center, Carmichael, California, United States
🇺🇸Fox Chase Cancer Center CCOP Research Base, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.